SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

PLRX

Pliant Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss reinforces the bearish sentiment for a pre-revenue biotech with no near-term catalysts until 2027 interim data. The $172.4M cash runway into H2 2028 provides a floor, but without a partnership or data catalyst, the stock is likely to drift lower. Monitor for any partnership or financing announcements given the $76M market cap.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.18
T+0 close · May 11, 2026 · via day close
Latest settled
−11.02%
T+60 · $1.05
Vs SPY
−15.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $1.18entry
  2. T+1 · 6mo ago 0.00%α −0.54% · $1.18
  3. T+5 · 6mo ago 0.00%α −0.08% · $1.18
  4. T+20 · 5mo ago −1.69%α +0.03% · $1.16
  5. T+60 · 3mo ago −11.02%α −15.40% · $1.05
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue biotech). Net loss narrowed to $20.0M from $56.2M a year ago due to lower R&D spend after terminating bexotegrast. The company highlighted early clinical progress for PLN-101095 in ICI-refractory tumors, including a complete response and two partial responses, but the EPS miss and absence of near-term catalysts cap the upside for a $76M market cap stock.

Key Financial Metrics

EPS
−$0.38
est −$0.36 · -5.6%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Q1 2026 EPS of -$0.38 missed consensus of -$0.36 (-6.2% miss)
  • Revenue was $0 (pre-revenue clinical-stage biotech)
  • Net loss narrowed to $20.0M from $56.2M YoY, driven by lower R&D spend after bexotegrast termination
  • Cash, cash equivalents and short-term investments of $172.4M expected to fund operations into H2 2028
  • First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027
  • Updated Phase 1 data at AACR showed 1 complete response, 2 partial responses in ICI-refractory tumors

Financial Impact

EPS miss of $0.02 per share vs consensus; net loss of $20.0M vs $56.2M YoY

epsnet losscash runway

Risk Factors

  • Clinical trial failure or delay for PLN-101095
  • Cash burn rate may accelerate if trials expand
  • No revenue and reliance on equity or debt financing
  • Competition from other checkpoint resistance therapies

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
9% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292302

Track record

8 reports on PLRX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
  2. Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
  3. May 11, 202627w ago 8-K Neutral 4/10 No price data
  4. May 11, 202627w ago Press Release Bearish 6/10 Viewing Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
  5. Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
  6. Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
  7. Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
  8. Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026